A Study to Evaluate Gevokizumab with Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers


About this study

The purpose of this study is to determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary effectiveness of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Metastatic disease not amenable to potentially curative surgery and with available
archival tumor tissue or fresh tumor tissue biopsy.

- Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST

For Cohort A:

- First line metastatic colorectal cancer.

For Cohort B:

- Second line metastatic colorectal cancer that has progressed on prior chemotherapy
administered for metastatic disease and which must include a fluoropyrimidine and

For Cohort C:

- Second line metastatic gastroesophageal cancer that has progressed on prior line of
chemotherapy administered for metastatic disease, and which must include a platinum agent
and fluoropyrimidine doublet.

For Cohort D:

- Second or third line metastatic renal cell carcinoma with a clear-cell component and has
received one or two lines of treatment for metastatic disease that included an
anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.

For subjects starting from Part 1a in Cohorts A and B:

- Serum hs-CRP at screening ≥ 10 mg/L.

- Not requiring immediate initiation of anti-cancer therapy per investigator's best

For subjects starting from Part 2 in Cohort C:

- Serum hs-CRP at screening ≥ 10 mg/L.

Exclusion Criteria:

For All Cohorts:

- Currently receiving any of the prohibited medications or has contraindications as
outlined in the protocol.

- Symptomatic brain metastases or brain metastases that require directed therapy (such
as focal radiotherapy or surgery).

- Suspected or proven immunocompromised state, or infections (as defined in the

- Conditions that have a high risk of clinically significant bleeding after
administration of anti-VEGF agents.

- Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular

For Cohort D:

- Concomitant medications, herbal supplements, and/or fruits and their juices that are
known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow
therapeutic window and are predominantly metabolized through CYP3A4/5.

- Impairment of GI function or GI disease that may significantly alter the absorption of

Other protocol-defined inclusion/exclusion criteria may apply

Eligibility last updated 6/8/22. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer